Perkin-Elmer
This article was originally published in The Gray Sheet
Executive Summary
Buyer is being sought for the firm's Analytical Instruments division following a review initiated in September 1998 to weigh strategic alternatives for the $600 mil.-a-year business ("The Gray Sheet" Sept. 14, 1998, p. 10). The AI unit markets a broad range of analytical chemistry systems used in clinical and biological analysis and in pharmaceutical development to identify and measure changes in properties of solids, liquids and gases. Perkin-Elmer would retain its $900 mil.-a-year PE Biosystems division and the newly formed Celera Genomics gene-based information joint venture with The Institute for Genomics Research